top of page

Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach

Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this program in the United States.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page